 Brentwood, Tenn, March 23, 2021 GLOBE NEWSWIRE -- IMAC Holdings, Inc. the Company or IMAC Nasdaq: IMAC, IMACW, a provider of innovative medical advancements and care specializing in regenerative and rehabilitation orthopedic treatments without the use of surgery or opioids, announced today the pricing of its underwritten registered public offering of 10,625,000 shares of its common stock at a public offering price of 1.60 per share, for total gross proceeds of 17.0 million. The net proceeds, after underwriting discounts, but before estimated expenses of the offering payable by IMAC, are expected to be approximately 16.0 million. All shares of common stock to be sold in the offering will be sold by the Company, except that the Company, together with its co-founder and chief operating officer as a selling stockholder, will grant the underwriter for the offering a 45-day option to purchase up to 15 of the shares of common stock in the offering. The offering is expected to close on or about March 26, 2021, subject to the satisfaction of customary closing conditions. 